Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zabedosertib in Moderate-to-Severe Atopic Dermatitis
NCT05656911Phase 2Completed
- Sponsor
- Bayer
- Start
- Dec 2022
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of zabedosertib in atopic dermatitis (AD), sponsored by Bayer. Started Dec 2022; status: completed.
02
Drugs
zabedosertib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05656911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05656911.